NASDAQ:RCEL Avita Medical (RCEL) Stock Price, News & Analysis $4.33 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$4.29 -0.04 (-1.02%) As of 05/29/2026 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avita Medical Stock (NASDAQ:RCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avita Medical alerts:Sign Up Key Stats Today's Range$4.23▼$4.5050-Day Range$3.63▼$5.6052-Week Range$3.22▼$7.12Volume162,462 shsAverage Volume266,960 shsMarket Capitalization$133.28 millionP/E RatioN/ADividend YieldN/APrice Target$7.25Consensus RatingHold Company Overview Avita Medical, Inc. (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures. Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S. Food and Drug Administration for acute thermal burn wounds. The company has since expanded its clinical indications and market access efforts into regions such as Australia, China and other parts of Asia. Avita collaborates with leading burn centers, academic institutions and investigator‐initiated trials to explore additional applications—ranging from chronic diabetic ulcers to vitiligo and hair restoration. Under the leadership of President and Chief Executive Officer Michael Perry, Avita Medical has emphasized the integration of its proprietary cell‐harvesting technology into standard burn and wound care protocols. The company maintains a global commercial infrastructure to support physician training, clinical research, and post‐market surveillance. Its strategic priorities include broadening clinical adoption of ReCell, pursuing new regulatory approvals and fostering partnerships to extend its regenerative platform into adjacent markets.AI Generated. May Contain Errors. Read More Avita Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreRCEL MarketRank™: Avita Medical scored higher than 52% of companies evaluated by MarketBeat, and ranked 536th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingAvita Medical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAvita Medical has a consensus price target of $7.25, representing about 67.4% upside from its current price of $4.33.Amount of Analyst CoverageAvita Medical has only been the subject of 4 research reports in the past 90 days.Read more about Avita Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avita Medical are expected to grow in the coming year, from ($1.29) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avita Medical is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avita Medical is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Avita Medical's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.86% of the float of Avita Medical has been sold short.Short Interest Ratio / Days to CoverAvita Medical has a short interest ratio ("days to cover") of 11.15, which indicates bearish sentiment.Change versus previous monthShort interest in Avita Medical has recently increased by 3.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvita Medical does not currently pay a dividend.Dividend GrowthAvita Medical does not have a long track record of dividend growth. News and Social Media2.4 / 5News SentimentN/A News SentimentAvita Medical has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Avita Medical this week, compared to 4 articles on an average week.Search Interest1 people have searched for RCEL on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Avita Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $8,480.00 in company stock, which represents 0.0064% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Avita Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,480.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.80% of the stock of Avita Medical is held by insiders.Percentage Held by Institutions27.66% of the stock of Avita Medical is held by institutions.Read more about Avita Medical's insider trading history. Receive RCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avita Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCEL Stock News HeadlinesAvita Medical (NASDAQ:RCEL) Lowered to "Sell" Rating by Wall Street ZenMay 24, 2026 | americanbankingnews.comAVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth TranscriptMay 22, 2026 | seekingalpha.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker. | Paradigm Press (Ad)AVITA Medical to Host Investor Webinar BriefingMay 17, 2026 | globenewswire.comBTIG Reaffirms Their Hold Rating on Avita Medical (RCEL)May 17, 2026 | theglobeandmail.comLake Street upgrades AVITA Medical (RCEL)May 16, 2026 | msn.comAvita (RCEL) Q1 2026 Earnings Call TranscriptMay 15, 2026 | theglobeandmail.comAVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comSee More Headlines RCEL Stock Analysis - Frequently Asked Questions How have RCEL shares performed this year? Avita Medical's stock was trading at $3.45 at the beginning of the year. Since then, RCEL stock has increased by 25.5% and is now trading at $4.33. How were Avita Medical's earnings last quarter? Avita Medical Inc. (NASDAQ:RCEL) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $19.25 million for the quarter, compared to analyst estimates of $18.30 million. Read the conference call transcript. Who are Avita Medical's major shareholders? Avita Medical's top institutional shareholders include Bank of America Corp DE (0.20%), Thompson Davis & CO. Inc. (0.13%), Quantinno Capital Management LP (0.07%) and Abel Hall LLC (0.05%). Insiders that own company stock include David D O'toole, Robert Mcnamara, Donna Shiroma, Suzanne Crowe, Jeremy Curnock Cook and James Corbett. View institutional ownership trends. How do I buy shares of Avita Medical? Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avita Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avita Medical investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Tesla (TSLA). Company Calendar Last Earnings5/14/2026Today5/31/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 RCEL's financial health is in the Green zone, according to TradeSmith. RCEL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:RCEL CIK1762303 Webwww.avitamedical.com Phone(833) 462-8482FaxN/AEmployees130Year Founded1992Price Target and Rating Average Price Target for Avita Medical$7.25 High Price Target$10.00 Low Price Target$3.00 Potential Upside/Downside+67.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.59 million Net Margins-62.67% Pretax Margin-62.68% Return on EquityN/A Return on Assets-78.92% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.38 Sales & Book Value Annual Sales$71.61 million Price / Sales1.86 Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-7.87Miscellaneous Outstanding Shares30,780,000Free Float29,915,000Market Cap$133.28 million OptionableOptionable Beta1.87 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:RCEL) was last updated on 6/1/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avita Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avita Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
